You are here:Home-Inhibitors & Agonists-Cell Cycle/DNA Damage-DNA Alkylator/Crosslinker

Request The Product List ofDNA Alkylator/Crosslinker DNA Alkylator/Crosslinker

Cat. No. Product Name CAS No. Information
PC-60562

Melflufen

380449-51-4

Melflufen (Melphalan flufenamide, J1) is a novel dipeptide and alkylating prodrug of melphalan, inhibits angiogenesis in vitro and in vivo; shows cytotoxic activity against lymphoma cell lines with IC50 of 0.011-0.92 uM, also shows significantly lower IC50 than melphalan in multiple myeloma cells; induces apoptosis even in melphalan- and bortezomib-resistant multiple myeloma cells.

Blood Cancer

Phase 3 Clinical

PC-45362

Thio-TEPA

52-24-4

An alkylating agent used to treat cancer that has been previously used in the palliation of a wide variety of neoplastic diseases.

Chemotherapeutic Agents

Approved

PC-45183

Temozolomide

85622-93-1

An alkylating agent used as a treatment of some brain cancers, astrocytoma and glioblastoma; a prodrug and an imidazotetrazine derivative of the alkylating agent dacarbazine.

Chemotherapeutic Agents

Approved

PC-45242

Cyclophosphamide hydrate

6055-19-2

A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities; used to treat cancers and autoimmune diseases.

Chemotherapeutic Agents

Approved

PC-45241

Cyclophosphamide

50-18-0

A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities; used to treat cancers and autoimmune diseases.

Chemotherapeutic Agents

Approved

PC-42280

Bisantrene

78186-34-2

A small molecule DNA intercalater with antineoplastic activity, does not exhibit cardiotoxicity compared with doxorubicin; induces both protein-associated DNA single-strand breaks and DNA-protein crosslinks in cancer cells.

PC-42644

Evofosfamide

918633-87-1

A potent and selective hypoxia-activated phosphoramidate DNA cross-linking mustard; selectively potent under hypoxia and stable to liver microsomes; inhibits H246 cells and HT29 cells with IC50 of 0.1 uM and 0.2 uM respectively; active in an in vivo MIA PaCa-2 pancreatic cancer orthotopic xenograft model.

Pancreatic Cancer

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com